Published in ChemMedChem on April 30, 2014
Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med (1997) 2.61
A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother (2004) 1.94
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov (2013) 1.64
Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J Med Chem (2004) 1.57
Pyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirus. Antimicrob Agents Chemother (1987) 1.30
Mechanism of the Dimroth rearrangement in adenosine. Biochem Biophys Res Commun (1975) 1.13
Sugar-modified N 6 -(3-methyl-2-butenyl)adenosine derivatives, N 6 -benzyl analogs, and cytokinin-related nucleosides containing sulfur or formycin. Biochemistry (1973) 1.08
The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol Aspects Med (2013) 1.06
Antiviral activity of C-5 substituted tubercidin analogues. J Med Chem (1984) 1.06
Pyrrolopyrimidine nucleosides. 3. The total synthesis of toyocamycin, sangivamycin, tubercidin, and related derivatives. J Am Chem Soc (1969) 1.01
ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC. BMC Cancer (2009) 0.99
Synthesis and anti-DNA viral activities in vitro of certain 2,4-disubstituted-7-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)pyrrolo[2,3-d d pyrimidine nucleosides. J Med Chem (1995) 0.87
Synthesis and significant cytostatic activity of 7-hetaryl-7-deazaadenosines. J Med Chem (2011) 0.84
Fluoro, alkylsulfanyl, and alkylsulfonyl leaving groups in suzuki cross-coupling reactions of purine 2'-deoxynucleosides and nucleosides. Org Lett (2005) 0.84
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin. J Med Chem (1987) 0.83
S(N)Ar displacements with 6-(fluoro, chloro, bromo, iodo, and alkylsulfonyl)purine nucleosides: synthesis, kinetics, and mechanism1. J Am Chem Soc (2007) 0.82
Synthesis of a 6-methyl-7-deaza analogue of adenosine that potently inhibits replication of polio and dengue viruses. J Med Chem (2010) 0.82
Adenosine kinase inhibitors. 5. Synthesis, enzyme inhibition, and analgesic activity of diaryl-erythro-furanosyltubercidin analogues. J Med Chem (2005) 0.82
Progress in 7-deazapurine - pyrrolo[2,3-d]pyrimidine - ribonucleoside synthesis. Curr Top Med Chem (2006) 0.82
Nucleic acid related compounds. 127. Selective N-deacylation of N,O-peracylated nucleosides in superheated methanol. J Org Chem (2005) 0.81
6-(Het)aryl-7-deazapurine ribonucleosides as novel potent cytostatic agents. J Med Chem (2010) 0.81
Synthesis of 2'-beta-C-methyl toyocamycin and sangivamycin analogues as potential HCV inhibitors. Bioorg Med Chem Lett (2005) 0.81
Xylotubercidin against herpes simplex virus type 2 in mice. Antimicrob Agents Chemother (1986) 0.81
Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin. J Med Chem (1989) 0.81
Adenosine kinase inhibitors. 2. Synthesis, enzyme inhibition, and antiseizure activity of diaryltubercidin analogues. J Med Chem (2000) 0.80
Identification of 5-Iodotubercidin as a genotoxic drug with anti-cancer potential. PLoS One (2013) 0.80
Inhibition of episomal hepatitis B virus DNA in vitro by 2,4-diamino-7- (2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-pyrrolo[2,3-d]pyrimidine. Antimicrob Agents Chemother (1995) 0.80
Synthesis, cytostatic, antimicrobial, and anti-HCV activity of 6-substituted 7-(het)aryl-7-deazapurine ribonucleosides. J Med Chem (2014) 0.79
Regiospecific N9 alkylation of 6-(heteroaryl)purines: shielding of N7 by a proximal heteroaryl C-H1. J Org Chem (2006) 0.79
Cell cycle arrest and cytochrome c-mediated apoptotic induction by MCS-5A is associated with up-regulation of p16(INK4a) in HL-60 cells. Bioorg Med Chem Lett (2010) 0.77
Synthesis and SAR of 2',3'-bis-O-substituted N(6), 5'-bis-ureidoadenosine derivatives: implications for prodrug delivery and mechanism of action. Bioorg Med Chem Lett (2012) 0.77
Synthesis of pyrrolo[2,3-d]pyrimidine nucleoside derivatives as potential anti-HCV agents. Bioorg Chem (2006) 0.77
5-Hydroxymethyltubercidin. Synthesis, biological activity, and role in pyrrolopyrimidine biosynthesis. J Med Chem (1973) 0.77
Antiproliferative and protein kinase binding activities of Some N6, 5'-bis-ureido 5'-amino-5'-deoxyadenosine derivatives. Nucleosides Nucleotides Nucleic Acids (2009) 0.76
Pyrrolopyrimidine Nucleosides. I. The Synthesis of 4-Substituted 7-(- D -Ribofuranosyl)pyrrolo[2,3-d]pyrimidines from Tubercidin. J Med Chem (1967) 0.76
The equilibrative nucleoside transporter family, SLC29. Pflugers Arch (2003) 3.00
Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation. J Antimicrob Chemother (2005) 2.14
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res (2004) 2.06
Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds. Eur J Med Chem (2006) 2.04
The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol (2005) 1.91
Influence of 2-substituent on the activity of imidazo[1,2-a] pyridine derivatives against human cytomegalovirus. Bioorg Med Chem (2002) 1.77
Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem (2005) 1.75
Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe (2011) 1.74
Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol (2003) 1.73
Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene (2003) 1.73
Synthesis and antiviral activity of new pyrazole and thiazole derivatives. Eur J Med Chem (2009) 1.71
Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ Res (2006) 1.63
Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci (2006) 1.60
Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res (2002) 1.57
Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res (2002) 1.55
In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother (2004) 1.54
Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells. PLoS One (2011) 1.52
Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. J Med Chem (2002) 1.51
The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev (2007) 1.50
Synthesis and antiviral activity of 2,4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy]pyrimidine and related compounds. Bioorg Med Chem (2004) 1.41
Hydantoin derivatives of L- and D-amino acids: synthesis and evaluation of their antiviral and antitumoral activity. Molecules (2006) 1.36
Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives. Eur J Med Chem (2008) 1.36
Design, synthesis, and biological evaluation of hybrid molecules containing alpha-methylene-gamma-butyrolactones and polypyrrole minor groove binders. J Med Chem (2004) 1.35
[(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging (2003) 1.35
5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity. J Med Chem (2003) 1.28
3,5-Bis(benzylidene)-4-oxo-1-phosphonopiperidines and related diethyl esters: Potent cytotoxins with multi-drug-resistance reverting properties. ChemMedChem (2009) 1.27
The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med Res Rev (2006) 1.24
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. J Virol (2005) 1.24
Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. Int J Biochem Cell Biol (2008) 1.23
Aryloxy phosphoramidate triesters as pro-tides. Mini Rev Med Chem (2004) 1.23
The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev (2009) 1.22
Cytotoxic 5-aryl-1-(4-nitrophenyl)-3-oxo-1,4-pentadienes mounted on alicyclic scaffolds. Eur J Med Chem (2006) 1.21
The cytotoxic properties and preferential toxicity to tumour cells displayed by some 2,4-bis(benzylidene)-8-methyl-8-azabicyclo[3.2.1] octan-3-ones and 3,5-bis(benzylidene)-1-methyl-4-piperidones. Eur J Med Chem (2008) 1.20
Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. J Biol Chem (2001) 1.18
Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones. Bioorg Chem (2004) 1.17
6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity. J Med Chem (2002) 1.16
Probing the catalytic mechanism of S-ribosylhomocysteinase (LuxS) with catalytic intermediates and substrate analogues. J Am Chem Soc (2009) 1.15
Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorg Med Chem Lett (2007) 1.15
The role of human nucleoside transporters in uptake of 3'-deoxy-3'-fluorothymidine. Mol Pharmacol (2008) 1.14
Molecular biology of nucleoside transporters and their distributions and functions in the brain. Curr Top Med Chem (2011) 1.14
Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother (2005) 1.13
Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: structural modulations of diaryltriazines with potent anti-HIV activity. Eur J Med Chem (2007) 1.11
Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides. J Med Chem (2005) 1.10
Transmembrane water-flux through SLC4A11: a route defective in genetic corneal diseases. Hum Mol Genet (2013) 1.09
The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations. Bioorg Med Chem (2006) 1.09
Synthesis, structural studies, and biological evaluation of some purine substituted 1-aminocyclopropane-1-carboxylic acids and 1-amino-1-hydroxymethylcyclopropanes. Nucleosides Nucleotides Nucleic Acids (2003) 1.07
Synthesis, conformational analysis and antiviral and antitumoral activity of new 1,2-disubstituted carbocyclic nucleosides. Eur J Med Chem (2002) 1.06
A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol (2005) 1.06
Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res (2008) 1.05
Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope. Antimicrob Agents Chemother (2010) 1.05
Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile. J Biol Chem (2010) 1.04
Vaginal microbiota and its role in HIV transmission and infection. FEMS Microbiol Rev (2013) 1.04
Synthesis and biological evaluation of 2- and 3-aminobenzo[b]thiophene derivatives as antimitotic agents and inhibitors of tubulin polymerization. J Med Chem (2007) 1.04
Cytotoxic analogues of 2,6-bis(arylidene)cyclohexanones. Eur J Med Chem (2003) 1.04
Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1). J Biol Chem (2011) 1.04
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. J Acquir Immune Defic Syndr (2010) 1.03
Structure-activity relationship of brominated 3-alkyl-5-methylene-2(5H)-furanones and alkylmaleic anhydrides as inhibitors of Salmonella biofilm formation and quorum sensing regulated bioluminescence in Vibrio harveyi. Bioorg Med Chem (2010) 1.02
Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. Virology (2006) 1.02
Hydroxyl ion addition to one-electron oxidized thymine: unimolecular interconversion of C5 to C6 OH-adducts. J Am Chem Soc (2013) 1.02
Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy. Biochem Pharmacol (2003) 1.02
Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells. ChemMedChem (2009) 1.02
Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. J Leukoc Biol (2006) 1.02
New antimony(III) bromide complexes with thioamides: synthesis, characterization, and cytostatic properties. Inorg Chem (2009) 1.02
Structure-activity relationship study on anti-HIV 6-desfluoroquinolones. J Med Chem (2008) 1.01
The nucleoside transport proteins, NupC and NupG, from Escherichia coli: specific structural motifs necessary for the binding of ligands. Org Biomol Chem (2005) 1.01
5'-O-tritylinosine and analogues as allosteric inhibitors of human thymidine phosphorylase. J Med Chem (2006) 1.01
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs (2010) 1.01
Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model. J Nucl Med (2010) 1.00
Human SLC2A9a and SLC2A9b isoforms mediate electrogenic transport of urate with different characteristics in the presence of hexoses. Am J Physiol Renal Physiol (2012) 1.00
Therapeutic strategies towards HIV-1 infection in macrophages. Antiviral Res (2006) 1.00
1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents. Bioorg Med Chem (2011) 1.00
Cytotoxic 1,3-diarylidene-2-tetralones and related compounds. Eur J Med Chem (2002) 0.99
Cloning and functional characterization of the human GLUT7 isoform SLC2A7 from the small intestine. Am J Physiol Gastrointest Liver Physiol (2004) 0.99
The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treat Res (2002) 0.99
Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. J Med Chem (2014) 0.98
Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology (2007) 0.98
Synthesis and antiviral activity of N9-[3-fluoro-2-(phosphonomethoxy)propyl] analogues derived from N6-substituted adenines and 2,6-diaminopurines. Bioorg Med Chem (2011) 0.98
Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase. J Biol Chem (2009) 0.98
Nucleic acid related compounds. 118. Nonaqueous diazotization of aminopurine derivatives. Convenient access to 6-halo- and 2,6-dihalopurine nucleosides and 2'-deoxynucleosides with acyl or silyl halides. J Org Chem (2003) 0.98
Red fluorescent protein pH biosensor to detect concentrative nucleoside transport. J Biol Chem (2009) 0.97
Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res (2007) 0.97
Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency. J Med Chem (2005) 0.97
Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. J Med Chem (2005) 0.97
Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection. Virology (2009) 0.97
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine. J Med Chem (2006) 0.97
Synthesis and anti-HIV properties of new water-soluble bis-functionalized[60]fullerene derivatives. Bioorg Med Chem Lett (2003) 0.97
Nucleoside transport as a potential target for chemotherapy in malaria. Curr Pharm Des (2007) 0.96
Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives. J Med Chem (2006) 0.96
Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies. Arthritis Res Ther (2006) 0.96
Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy. Biochem Pharmacol (2007) 0.95
Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney. Am J Physiol Renal Physiol (2007) 0.95
A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2. J Infect Dis (2010) 0.95
Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates. J Med Chem (2010) 0.95
Studies of nucleoside transporters using novel autofluorescent nucleoside probes. Biochemistry (2006) 0.95